Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab + nab-paclitaxel + cisplatin in borderline resectable esophageal squamous cell carcinoma
ChiCTR2100051514Phase 2Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoints: Patient pathology assessment, Patient imaging assessment and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
tislelizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100051514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051514.